US equities |
MU $931.24 ▲+1.87% NVDA $217.23 ▼-1.84% SNDK $1,394.83 ▼-0.61% AMD $562.23 ▼-1.50% SPCX $148.62 ▼-2.33% INTC $95.37 ▼-2.80% AAPL $342.00 ▼-0.28% MSFT $539.44 ▲+1.08%
FinancialContent

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.65 +0.62 (+2.29%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
4 Analysts Assess Amylyx Pharma: What You Need To Know ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings For Amylyx Pharma ↗
 
Via Benzinga
News headline image
6 Analysts Assess Amylyx Pharma: What You Need To Know ↗
 
Via Benzinga
News headline image
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November ↗
 
Via Benzinga
News headline image
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week ↗
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder. 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday? ↗
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024 ↗
AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder ↗
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >